5-Amino-1MQ Dosage: What the 'Protocols' Use and Why None Are Clinically Validated

Search "5-Amino-1MQ dosage" and you'll find the same tidy answer repeated across vendor pages and clinic blogs: take a 50 to 150 mg oral capsule once a day, on an empty stomach, for eight to twelve weeks. The number is presented as if it came off a drug label. It did not. There is no clinically established human dose for 5-Amino-1MQ, because there is no completed human trial of 5-Amino-1MQ at all. Every dose you see quoted is an extrapolation — from mouse studies, from a manufacturer's suggested-use line, or from one clinic copying another. This article lays out what those numbers actually are, where they come from, and why "a dose people take" is a very different thing from "a dose proven safe and effective in people."

We are not going to hand you a protocol. This is not medical advice. 5-Amino-1MQ (5-amino-1-methylquinolinium) is an unapproved research chemical, and the dosing question is genuinely unanswered. What follows is the honest version of what's known — and how little of it is about humans.

The Honest Headline: The Evidence Base Is a Mouse Study

Start with the fact everything else depends on. The reason 5-Amino-1MQ exists as a "metabolic" compound at all traces back to a single line of preclinical research: it is a small-molecule inhibitor of nicotinamide N-methyltransferase (NNMT), an enzyme implicated in adipose-tissue energy metabolism. The headline finding is from a 2018 mouse study, in which membrane-permeable NNMT inhibitors reversed diet-induced obesity in mice — reducing body weight and fat mass in animals fed a high-fat diet¹. That paper is the engine behind essentially every "5-Amino-1MQ for fat loss" claim online.

The rationale for inhibiting NNMT in the first place came from earlier work showing that knocking down NNMT protected mice against diet-induced obesity, linking the enzyme to cellular energy metabolism and fat storage². So the mechanistic story is real and was published in serious journals. But read what those studies are: they are mouse experiments. There is no human dose-finding trial, no human efficacy trial, and no human safety trial of 5-Amino-1MQ to anchor a number to.

Where the "50–150 mg/day" Number Actually Comes From

So if there's no human trial, where does the confident capsule dose come from? Three places, none of them a clinical study.

Extrapolation from the animal work. The mouse studies dosed NNMT inhibitors by body weight, typically in milligrams per kilogram, delivered to animals in a controlled lab setting¹. Taking a mouse mg/kg dose and converting it to a flat human capsule strength is not how pharmacology works — interspecies metabolism differs enormously, and allometric scaling is not a simple multiplication. A dose that reduced fat mass in a high-fat-fed mouse¹ tells you nothing reliable about what a human body needs, tolerates, or clears.

Vendor "suggested use" lines. Research-chemical sellers print a suggested-use figure to make the product look usable. That number is a marketing choice, not a finding. It is often the source the clinic blogs then cite as if it were established.

Copy-paste folklore. Once a figure like "50–150 mg/day" enters the community, it propagates — one page quotes another, and the original (absent) derivation is forgotten. The precision is an illusion of consensus, not evidence of one.

The bottom line on the number: it is borrowed and unvalidated. We treat it the same way across the site — including in our broader review of peptides and small molecules for fat loss, where the recurring pattern is striking animal data attached to invented human doses.

Oral Capsules vs. Reconstituted Forms: Both Routes Are Unsettled

5-Amino-1MQ is sold mainly as oral capsules, which fits its identity as a small, orally relevant molecule rather than an injectable peptide. But you will also see it offered as a powder to be reconstituted, or bundled into injectable "blends." Vendors quote different doses by route — which would only make sense if route-specific human absorption were known. It isn't. There is no human bioavailability study for any route, so any oral-to-injectable "equivalent" dose you see is invented.

If you've landed here because a product arrived as a powder with mixing instructions, understand that the arithmetic of turning a labeled milligram amount into a per-dose volume — covered in our guide to how to reconstitute peptides — does not make the resulting dose validated. It only makes it measurable. You can calculate a precise number from an imprecise, unproven product and still have no idea whether it is safe or effective.

The Grey-Market Problem: You May Not Be Dosing What You Think

Here is the practical dosing risk the protocols never mention: because no approved, quality-controlled 5-Amino-1MQ product exists, the actual amount of compound in a "50 mg" capsule is unverifiable. These products are sold as research chemicals, typically labeled "not for human consumption," with no regulatory oversight of identity, purity, or content. Independent testing of grey-market metabolic compounds and peptides has repeatedly turned up under-dosed, over-dosed, mislabeled, and contaminated products.

That makes precise dosing a false comfort. A person carefully measuring out "100 mg/day" from a research-chemical capsule may be taking a wildly different amount than the label claims — or a different substance entirely. We cover this supply-and-legality gray zone in depth in where to buy peptides and the "research chemical" legality question, and you can sanity-check vendor claims against our research tools.

"Research Use" Is Not a Loophole — It's the Whole Status

The "for research use only" framing on these products is not a clever workaround that makes a personal dose acceptable. It is an accurate description of where the science actually sits. 5-Amino-1MQ has been studied as a research-grade NNMT inhibitor in animals¹²; it has not been developed into an approved human medicine with an established dose, a safety profile, or a maximum tolerated dose. The label is telling you the truth about the evidence: this is a compound for the lab bench, not a dosed therapeutic.

So when someone asks "how much 5-Amino-1MQ should I take?", the honest answer is that the question assumes a human dosing framework that does not exist. There is no studied human dose to be "right" or "wrong" about.

Bottom Line

The honest answer to "what is the 5-Amino-1MQ dosage?" is: nobody knows, because it has never been established in a human trial. The "50 to 150 mg/day oral capsule" figure you see everywhere is an extrapolation — derived loosely from mouse NNMT-inhibitor studies that reversed diet-induced obesity in animals¹, built on earlier mouse work linking NNMT to fat storage², and then hardened into folklore through vendor suggested-use lines and clinic copy-paste. None of it is anchored to a human dose-finding study, because none has been done.

Layer on an unverifiable grey-market supply, the unsettled oral-versus-reconstituted route question, and a "research use only" status that reflects the genuine state of the evidence, and the dosing conversation collapses into a simpler one: this is an unproven, unapproved research compound with no human-established dose. The mouse science is a reason to run human trials — not a license to pick a milligram number and swallow it. For the wider fat-loss picture and how 5-Amino-1MQ fits among the other mostly-unproven options, see our peptides for fat loss review, and the full mechanism breakdown in our 5-Amino-1MQ evidence article.